Early antibody therapy can induce long-lasting immunity to SHIV

Nature

Volumn 543, Issue 7646, 2017, Pages 559-563

  Nishimura, Yoshiaki ^a   Gautam, Rajeev ^a   Chun, Tae Wook ^a   Sadjadpour, Reza ^a   Foulds, Kathryn E ^a   Shingai, Masashi ^a   Klein, Florian ^b   Gazumyan, Anna ^c   Golijanin, Jovana ^c   Donaldson, Mitzi ^a   Donau, Olivia K ^a   Plishka, Ronald J ^a   Buckler White, Alicia ^a   Seaman, Michael S ^d   Lifson, Jeffrey D ^e   Koup, Richard A ^a   Fauci, Anthony S ^a   Nussenzweig, Michel C ^c   Martin, Malcolm A ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF COLOGNE   (Germany)

^c ROCKEFELLER UNIVERSITY   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROADLY NEUTRALIZING ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; EMTRICITABINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 10-1074; MONOCLONAL ANTIBODY 3BNC117; NEUTRALIZING ANTIBODY; RALTEGRAVIR; TENOFOVIR; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIBODY; ANTIGEN; CELLS AND CELL COMPONENTS; DISEASE CONTROL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNITY; IMMUNOASSAY; INDUCED RESPONSE; MAMMAL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIRETROVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG HALF LIFE; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOTHERAPY; IN VIVO STUDY; MALE; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REBOUND; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SINGLE DRUG DOSE; VIREMIA; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; HALF LIFE TIME; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MULTIMODALITY CANCER THERAPY; PASSIVE IMMUNIZATION; SIMIAN IMMUNODEFICIENCY VIRUS; VIROLOGY;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS; MACACA; MUS; REPLICATION COMPETENT VIRUSES; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

ANIMALS; ANTI-HIV AGENTS; ANTIBODIES, NEUTRALIZING; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; FEMALE; HALF-LIFE; HIV; HIV ANTIBODIES; HIV INFECTIONS; IMMUNIZATION, PASSIVE; MACACA MULATTA; MALE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL LOAD; VIREMIA; VIRUS REPLICATION;

EID: 85016135760     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature21435     Document Type: Article

References (36)

1. Barouch, D. H. et al. Therapeutic efcacy of potent neutralizing HIV-1-specifc monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503, 224-228 (2013).
2. Bolton, D. L. et al. Human immunodefciency virus type 1 monoclonal antibodies suppress acute simian-human immunodefciency virus viremia and limit seeding of cell-associated viral reservoirs. J. Virol. 90, 1321-1332 (2016).
3. Caskey, M. et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522, 487-491 (2015).
4. Gautam, R. et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature 533, 105-109 (2016).
5. Halper-Stromberg, A. et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 158, 989-999 (2014).
6. Hessell, A. J. et al. Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. Nature Med. 22, 362-368 (2016).
7. Horwitz, J. A. et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc. Natl Acad. Sci. USA 110, 16538-16543 (2013).
8. Klein, F. et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492, 118-122 (2012).
9. Lynch, R. M. et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci. Transl. Med. 7, 319ra206 (2015).
10. Moldt, B. et al. Highly potent HIV-specifc antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl Acad. Sci. USA 109, 18921-18925 (2012).
11. Shingai, M. et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J. Exp. Med. 211, 2061-2074 (2014).
12. Shingai, M. et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503, 277-280 (2013).
13. Mouquet, H. et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc. Natl Acad. Sci. USA 109, E3268-E3277 (2012).
14. Scheid, J. F. et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633-1637 (2011).
15. + T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 200, 749-759 (2004).
16. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodefciency virus type 1 infection. J. Virol. 68, 6103-6110 (1994).
17. Koup, R. A. et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodefciency virus type 1 syndrome. J. Virol. 68, 4650-4655 (1994).
18. Davey, R. T., Jr et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl Acad. Sci. USA 96, 15109-15114 (1999).
19. Chun, T. W. et al. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc. Natl Acad. Sci. USA 95, 8869-8873 (1998).
20. Buzon, M. J. et al. Long-term antiretroviral treatment initiated at primary HIV-1 infection afects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells. J. Virol. 88, 10056-10065 (2014).
21. Sáez-Cirión, A. et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 9, e1003211 (2013).
22. Lifson, J. D. et al. Containment of simian immunodefciency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment. J. Virol. 74, 2584-2593 (2000).
23. Schoofs, T. et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science 352, 997-1001 (2016).
24. Igarashi, T. et al. Human immunodefciency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nature Med. 5, 211-216 (1999).
25. Liu, J. et al. Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus. Science 353, 1045-1049 (2016).
26. Lu, C. L. et al. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science 352, 1001-1004 (2016).
27. Gautam, R. et al. Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodefciency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies. J. Virol. 86, 8516-8526 (2012).
28. Nishimura, Y. et al. Generation of the pathogenic R5-tropic simian/human immunodefciency virus SHIVAD8 by serial passaging in rhesus macaques. J. Virol. 84, 4769-4781 (2010).
29. Shingai, M. et al. Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains. Proc. Natl Acad. Sci. USA 109, 19769-19774 (2012).
30. Bournazos, S., DiLillo, D. J. & Ravetch, J. V. The role of Fc-Fcγ R interactions in IgG-mediated microbial neutralization. J. Exp. Med. 212, 1361-1369 (2015).
31. Endo, Y. et al. Short-and long-term clinical outcomes in rhesus monkeys inoculated with a highly pathogenic chimeric simian/human immunodefciency virus. J. Virol. 74, 6935-6945 (2000).
32. Hansen, S. G. et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473, 523-527 (2011).
33. Foulds, K. E., Donaldson, M. & Roederer, M. OMIP-005: quality and phenotype of antigen-responsive rhesus macaque T cells. Cytometry A 81, 360-361 (2012).
34. + T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nature Med. 5, 651-655 (1999).
35. Myers, L. E., McQuay, L. J. & Hollinger, F. B. Dilution assay statistics. J. Clin. Microbiol. 32, 732-739 (1994).
36. Fukazawa, Y. et al. B cell follicle sanctuary permits persistent productive simian immunodefciency virus infection in elite controllers. Nature Med. 21, 132-139 (2015).